Floatz logo

ANTI-CD70 ANTIBODY-DRUG CONJUGATE SGN-CD70A

Follicular Lymphoma, Grade 3

Seagen Inc.antibody_drug_conjugatePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

210 Active assets in the Follicular Lymphoma, Grade 3 cohort.

Asset / SponsorPhaseRating
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 2/3BBB
Romidepsin
City of Hope Medical Center
Phase 2BBB
Busulphan
Masonic Cancer Center, University of Minnesota
Phase 2/3BBB
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 3BBB
Irinotecan
University of Michigan Rogel Cancer Center
Phase 2BBB

View all 50 →

Same molecule, other indications

ANTI-CD70 ANTIBODY-DRUG CONJUGATE SGN-CD70A is also rated in:

mantle cell lymphomaDormant
CC
Indicative ·
47 / 100
View asset →
diffuse large B-cell lymphomaDormant
CC
Indicative ·
47 / 100
View asset →
renal cell carcinomaDormant
CC
Indicative ·
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →